Yahoo Finance • last month
FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), today clarified that a Schedule 13D filing by Frazier Life Sciences, which is expected to be filed later today, August 20, will include a... Full story
Yahoo Finance • 2 months ago
Earnings Call Insights: Phathom Pharmaceuticals (PHAT) Q2 2025 MANAGEMENT VIEW * Steven L. Basta, CEO, indicated that the quarter marked "a meaningful inflection point for Phathom" as the company builds a growth-oriented and profitable... Full story
Yahoo Finance • 2 months ago
PHATHOM PHARMACEUTICALS (NASDAQ:PHAT) BEATS Q2 REVENUE AND EPS ESTIMATES, SHARES RISE IN PREMARKET Phathom Pharmaceuticals (NASDAQ:PHAT [https://www.chartmill.com/stock/quote/PHAT]) reported second-quarter 2025 financial results that surp... Full story
Yahoo Finance • 2 months ago
Management to host conference call on Thursday, August 7, 2025, at 8:00 am EDT FLORHAM PARK, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and com... Full story
Yahoo Finance • 3 months ago
FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announce... Full story
Yahoo Finance • 4 months ago
[FDA headquarters in Washington DC.] JHVEPhoto/iStock Editorial via Getty Images * Phathom Pharmaceuticals (NASDAQ:PHAT [https://seekingalpha.com/symbol/PHAT]) said that the U.S. FDA has updated its "Orange Book" to reflect that Voquezn... Full story
Yahoo Finance • 4 months ago
FLORHAM PARK, N.J., June 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announce... Full story
Yahoo Finance • 4 months ago
[Going Up] Richard Drury Phathom Pharmaceuticals has shot up ~125% in Friday trading after the U.S. FDA granted their Citizen Petition regarding the expiration date of new chemical entity exclusivity for their drug Voquezna (vonoprazan).... Full story
Yahoo Finance • 4 months ago
FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom’s Citizen Petition filed on December 11, 2024 and co... Full story
Yahoo Finance • 5 months ago
• Management to host conference call on Thursday, May 1, 2025, at 8:00 am EDT FLORHAM PARK, N.J., April 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and com... Full story
Yahoo Finance • 6 months ago
FLORHAM PARK, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced th... Full story
Yahoo Finance • 6 months ago
FLORHAM PARK, N.J., April 03, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced tod... Full story
Yahoo Finance • 6 months ago
FLORHAM PARK, N.J., April 01, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announc... Full story
Yahoo Finance • 7 months ago
VOQUEZNA® (vonoprazan) generated $55.3 million in 2024 net revenues in its first full year of launch, driven by strong demand, including $29.7 million in Q4, an 81% increase from Q3Over 300,000 filled prescriptions for VOQUEZNA products, l... Full story
Yahoo Finance • 7 months ago
Management to host conference call on Thursday, March 6, 2025, at 8:30 am ET FLORHAM PARK, N.J., Feb. 24, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and comme... Full story
Yahoo Finance • 8 months ago
FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced toda... Full story
Yahoo Finance • 2 years ago
Phathom Pharmaceuticals Amendment provides more favorable terms including a 14-month extension of the interest-only period and maturity date until December 2027 Up to an additional $100 million in non-dilutive capital available subject t... Full story
Yahoo Finance • 2 years ago
VOQUEZNA, the first and only FDA-approved potassium-competitive acid blocker (PCAB), is now available through major retail pharmacies and BlinkRx, an end-to-end digital fulfillment channel VOQUEZNA tablets in 30-count bottles are now comme... Full story
Yahoo Finance • 2 years ago
NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary duty. To obtain additional informatio... Full story
Yahoo Finance • 2 years ago
PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT) (“Phathom”) on behalf of the company’s investors. Since August 2023, shares of Phathom’s com... Full story